2017

December 18, 2017
Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis
December 15, 2017
Sanofi: FDA lifts clinical hold on fitusiran
December 13, 2017
Sanofi and Regeneron announce positive topline pivotal results for PD-1 antibody cemiplimab in advanced cutaneous squamous cell carcinoma
December 11, 2017
FDA Approves Sanofi's Admelog® (insulin lispro injection)
December 4, 2017
Sanofi's Toujeo® met main objective in head-to-head study versus insulin degludec
December 1, 2017
Sanofi ends development of Clostridium difficile vaccine
November 30, 2017
Elias Zerhouni, President of Sanofi R&D, wins 'Executive of the Year' at annual Scrip Awards
November 29, 2017
Sanofi updates information on dengue vaccine
November 9, 2017
Sanofi, Principia agree to develop multiple sclerosis drug candidate
November 2, 2017
Sanofi and Alnylam present positive complete results from APOLLO Phase 3 study of investigational patisiran in hereditary ATTR (hATTR) amyloidosis patients with polyneuropathy
November 2, 2017
Sanofi : Q3 2017 Business EPS up 1.1% at CER FY 2017 Guidance Confirmed
October 24, 2017
Sanofi Files Suit in the U.S. to Defend Its Patent Rights on Lantus® and Lantus® SoloStar®
October 16, 2017
Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
October 12, 2017
Sanofi invests €170 million in new vaccine production facility in France
October 11, 2017
Sanofi: Availability of the Pre-quarterly Results Communication
October 2, 2017
Sanofi Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular
September 28, 2017
Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
September 20, 2017
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
September 16, 2017
Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
September 11, 2017
Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
September 8, 2017
Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma
September 7, 2017
Sanofi rated AA by Scope Ratings
August 28, 2017
Sanofi completes the acquisition of Protein Sciences
August 8, 2017
Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
July 31, 2017
Sanofi: Online Availability of Sanofi Group's Half-Year Financial Report for 2017
July 31, 2017
Sanofi Raises FY 2017 Business EPS(1) Guidance to Broadly Stable at CER(2)
July 21, 2017
Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
July 18, 2017
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
July 12, 2017
Sanofi: Availability of the Pre-quarterly Results Communication
July 11, 2017
Sanofi to acquire Protein Sciences
July 10, 2017
Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...
June 27, 2017
Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
June 15, 2017
Sanofi Launches "Action 2017", a Worldwide Employee Stock Purchase Plan
June 14, 2017
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
June 11, 2017
Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia
May 22, 2017
Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients